Topical vitamin D is approved by the US Food and Drug Administration for the treatment of psoriasis but is also used off-label in the treatment of a variety of cutaneous diseases despite a lack of evidence-based guidelines.
Objective:
The objective of this study was to provide evidence-based clinical guidelines for the off-label use of topical vitamin D in the treatment of dermatologic disease.
Methods:
A systematic literature review was conducted via the MEDLINE, Embase, and CENTRAL databases for off-label uses of topical vitamin D analogues in the treatment of dermatologic disease other than psoriasis. The data were synthesized, and evidence-based recommendations were rendered according to the highest level of evidence available.
Results:
A total of 165 articles met the inclusion criteria. A moderate to strong recommendation was given for the use of topical vitamin D in combination with corticosteroids and phototherapy in vitiligo and as monotherapy for various ichthyoses, morphea, pityriasis alba, prurigo nodularis, and polymorphous light eruption. There is evidence showing that topical vitamin D is ineffective in the treatment of actinic keratosis, seborrheic keratosis, lichen planus, seborrheic dermatitis, alopecia areata, chemotherapy-induced alopecia, and hypertrophic scars.
Conclusion:
Topical vitamin D analogues have an important role in the off-label treatment of dermatologic disease, but higher quality studies are still required.
Get full access to this article
View all access options for this article.
References
1.
AshcroftDMPoALWilliamsHCGriffithsCE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ2000;320:963–7, doi: 10.1136/bmj.320.7240.963.
2.
TakahashiHIbeMKinouchiM. Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci2003;31:21–8, doi: 10.1016/S0923-1811(02)00136-6.
3.
Berth-JonesJHutchinsonPE. Vitamin D analogues and psoriasis. Br J Dermatol1992;127:71–8, doi:10.1111/j.1365-2133. 1992.tb08035.x.
4.
BleikerTOBourkeJFMumfordRHutchinsonPE. Long-term outcome of severe chronic plaque psoriasis following treatment with high-dose topical calcipotriol. Br J Dermatol1998;139:285–6, doi:10.1046/j.1365-2133.1998.02367.x.
5.
StumpfWESarMReidFA. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science1979;206:1188–90, doi:10. 1126/science.505004.
6.
GerritsenMJBoezemanJBvan Vlijmen-WillemsIMvan de KerkhofPC. The effect of tacalcitol (1,24(OH)2D3) on cutaneous inflammation, epidermal proliferation and keratinization in psoriasis: a placebo-controlled, double-blind studyBr J Dermatol1994;131:57–63, doi:10.1111/j.1365-2133.1994.tb08458.x.
7.
SrviastavaMDDeLucaHAmbrusJL. Inhibition of IL-6 and IL-8 production in human fibroblast cell lines by 1,25 (OH)2 vitamin D3 and two of its analogs with lower calcemic activity. Res Commun Chem Pathol Pharmacol1994;83:145–50.
8.
KragballeKWildfangIL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes. Arch Dermatol Res1990;282:164–7, doi:10.1007/BF00372616.
9.
KorverJEVissersWHvan RensDW. A double-blind, randomized quantitative comparison of calcitriol ointment and calcipotriol ointment on epidermal cell populations, proliferation and differentiation. Br J Dermatol2007;156:130–7, doi:10.1111/j.1365-2133.2006.07561.x.
10.
BagotMCharueDLescsMC. Immunosuppressive effects of 1,25-dihydroxyvitamin D3 and its analogue calcipotriol on epidermal cells. Br J Dermatol1994;130:424–31, doi:10.1111/j.1365-2133.1994.tb03373.x.
11.
FelicianiCPourSMAllegrettiT. IL-1alpha, IL-6 and TNF-alpha in cutaneous lesions of lupus erythematosus are inhibited by topical application of calcipotriol. Int J Immunopathol Pharmacol1995;8:199–207.
12.
Rostkowska-NadolskaBSliupkas-DyrdaEPotykaJ. Vitamin D derivatives: calcitriol and tacalcitol inhibits interleukin-6 and interleukin-8 expression in human nasal polyp fibroblast cultures. Adv Med Sci2010;55:86–92.
13.
OsborneJEHutchinsonPE. Vitamin D and systemic cancer: is this relevant to malignant melanoma?Br J Dermatol2002;147: 197–213, doi:10.1046/j.1365-2133.2002.04960.x.
14.
LiberatiAAltmanDGTetzlaffJ. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med2009;151:W65–94, doi:10.7326/0003-4819-151-4-200908180-00136.
15.
StroupDFBerlinJAMortonSC. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA2000;283:2008–12, doi:10.1001/jama. 283.15.2008.
16.
HasegawaTSugaYMizunoY. Efficacy of photodynamic therapy with topical 5-aminolevulinic acid using intense pulsed light for Bowen's disease. J Dermatol2010;37:623–8, doi:10.1111/j.1346-8138.2010.00850.x.
17.
BilacDBErmertcanATSahinMTOzturkcanS. Two therapeutic challenges: facial vitiligo successfully treated with 1% pimecrolimus cream and 0.005% calcipotriol cream. J Eur Acad Dermatol Venereol2009;23:72–3, doi:10.1111/j.1468-3083. 2008.02668.x.
18.
ChiaveriniCPasseronTOrtonneJP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol2002;16:137–8, doi:10.1046/j.1468-3083.2002.00407.x.
19.
GargoomAMDuwebGAElzorghanyAH. Calcipotriol in the treatment of childhood vitiligo. Int J Clin Pharmacol Res2004;24:11–4.
20.
KoseORiza GurAKurumluZErolE. Calcipotriol ointment versus clobetasol ointment in localized vitiligo: an open, comparative clinical trial. Int J Dermatol2002;41:616–8, doi:10.1046/j.1365-4362.2002.01486_3.x.
21.
KumaranMSKaurIKumarB. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol2006;20:269–73, doi:10.1111/j.1468-3083.2006.01420.x.
22.
TravisLBSilverbergNB. Calcipotriene and corticosteroid combination therapy for vitiligo. Pediatr Dermatol2004;21:495–8, doi:10.1111/j.0736-8046.2004.21418.x.
23.
XingCXuA. The effect of combined calcipotriol and betamethasone dipropionate ointment in the treatment of vitiligo: an open, uncontrolled trial. J Drugs Dermatol2012;11:e52–4.
24.
AmeenMExarchouVChuAC. Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. Br J Dermatol2001;145:476–9, doi:10.1046/j.1365-2133.2001.04381.x.
25.
AmanoHAbeMIshikawaO. First case report of topical tacalcitol for vitiligo repigmentation. Pediatr Dermatol2008;25: 262–4, doi:10.1111/j.1525-1470.2008.00648.x.
26.
KatayamaIAshidaMMaedaA. Open trial of topical tacalcitol [1 alpha 24(OH)2D3] and solar irradiation for vitiligo vulgaris: upregulation of c-Kit mRNA by cultured melanocytes. Eur J Dermatol2003;13:372–6.
27.
OisoNKawadaA. Freckling promoted by topical tacalcitol in a Japanese boy with left eyelid vitiligo. Pediatr Dermatol2012;29: 671–2, doi:10.1111/j.1525-1470.2011.01559.x.
28.
ParsadDSainiRNagpalR. Calcipotriol in vitiligo: a preliminary study. Pediatr Dermatol1999;16:317–20, doi:10.1046/j.1525-1470.1999.00083.x.
29.
Rodriguez-MartinMGarcia BustinduyMSaez RodriguezMNoda CabreraA. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol2009; 160:409–14, doi:10.1111/j.1365-2133.2008.08906.x.
30.
SarmaNSinghAK. Topical calcipotriol in childhood vitiligo: an Indian experience. Int J Dermatol2004;43:856–9, doi:10.1111/j.1365-4632.2004.02344.x.
31.
WhittonMEPinartMBatchelorJ. Interventions for vitiligo. Cochrane Database Syst Rev2010;(1:)CD003263.
32.
AdaSSahinSBoztepeG. No additional effect of topical calcipotriol on narrow-band UVB phototherapy in patients with generalized vitiligo. Photodermatol Photoimmunol Photomed2005;21:79–83, doi:10.1111/j.1600-0781. 2005.00139.x.
33.
ArcaETastanHBErbilAH. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol2006;33:338–43, doi:10.1111/j.1346-8138.2006.00079.x.
34.
DograSParsadD. Combination of narrowband UV-B and topical calcipotriene in vitiligo. Arch Dermatol2003;139, 393, doi:10.1001/archderm.139.3.393.
35.
GoktasEOAydinFSenturkN. Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. J Eur Acad Dermatol Venereol2006;20:553–7, doi:10.1111/j.1468-3083.2006.01546.x.
36.
HartmannALurzCHammH. Narrow-band UVB311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. Int J Dermatol2005;44:736–42, doi:10.1111/j.1365-4632.2004.02154.x.
37.
KullavanijayaPLimHW. Topical calcipotriene and narrowband ultraviolet B in the treatment of vitiligo. Photodermatol Photoimmunol Photomed2004;20:248–51, doi:10.1111/j.1600-0781.2004.00114.x.
38.
LeoneGPacificoAIacovelliP. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol2006; 31:200–5, doi:10.1111/j.1365-2230.2005.02037.x.
39.
LottiTBuggianiGTroianoM. Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther2008;21Suppl 1:S20–6, doi:10.1111/j.1529-8019.2008.00198.x.
40.
UksalUBorluMAtasavunCFerahbasA. Comparison of four treatment regimens for vitiligo in children. Eur J Pediatr Dermatol2002;12:231–4.
41.
GamilHAttwaEGhonemyS. Narrowband ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of generalized vitiligo. Clin Exp Dermatol2010;35:919–21, doi:10.1111/j.1365-2230.2010.03838.x.
42.
BaysalVYildirimMErelAKesiciD. Is the combination of calcipotriol and PUVA effective in vitiligo?J Eur Acad Dermatol Venereol2003;17:299–302, doi: 10.1046/j. 1468-3083. 2003.00795.x.
43.
CherifFAzaizMIBen HamidaA. Calcipotriol and PUVA as treatment for vitiligo. Dermatol Online J2003;9(5):4.
44.
ErmisOAlpsoyECetinLYilmazE. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol2001;145:472–5, doi: 10.1046/j.1365-2133.2001. 04286.x.
45.
ParsadDPandhiRDograSKumarB. Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiliginous patches. J Am Acad Dermatol2004;50:63–7, doi: 10. 1016/S0190-9622(03)00786-2.
46.
ParsadDSainiRVermaN. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology1998;197:167–70, doi:10.1159/000017991.
47.
ShehzadAKhurshidKPalSSHaroonTS. Topical calcipotriol versus oral psoralen-UVA (PUVA) and topical calcipotriol in the treatment of vitiligo in type IV skin. J Pak Assoc Dermatol2007; 17:89–94.
48.
YalcinBSahinSBukulmezG. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: a preliminary study. J Am Acad Dermatol2001;44:634–7, doi:10.1067/mjd.2001.112357.
49.
GoldingerSMDummerRSchmidP. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol2007;21:504–8.
50.
Lu-yanTWen-wenFLei-hongX. Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. Photodermatol Photoimmunol Photomed2006;22:310–4, doi:10.1111/j.1600-0781.2006. 00250.x.
51.
MouzakisJALiuSCohenG. Rapid response of facial vitiligo to 308nm excimer laser and topical calcipotriene. J Clin Aesthet Dermatol2011;4:41–4.
52.
OhSHKimTJeeH. Combination treatment of nonsegmental vitiligo with a 308-nm xenon chloride excimer laser and topical high-concentration tacalcitol: a prospective, single-blinded, paired, comparative study. J Am Acad Dermatol2011;65: 428–30, doi: 10.1016/j.jaad.2010.12.007.
53.
AbeMYasudaMYokoyamaYIshikawaO. Successful treatment of combination therapy with tacalcitol lotion associated with sunscreen for localized Darier's disease. J Dermatol2010;37:718–21, doi:10.1111/j.1346-8138.2010.00910.x.
54.
AokiTHashimotoHKosekiS. 1alpha,24-Dihydroxyvitamin D3 (tacalcitol) is effective against Hailey-Hailey disease both in vivo and in vitro. Br J Dermatol1998; 139: 897–901, doi: 10.1046/j. 1365-2133.1998.02522.x.
55.
BianchiLChimentiMSGiuntaA. Treatment of Hailey-Hailey disease with topical calcitriol. J Am Acad Dermatol2004;51:475–7, doi:10.1016/j.jaad.2003.10.668.
56.
CannataGEIsolaPMVerriniA. Hailey-Hailey disease: local treatment with tacalcitol (1 alpha, 24-dihydroxyvitamin D3). Int J Med Biol Environ1999;27:115–7.
57.
HayashiH. Treatment of Grover's disease with tacalcitol. Clin Exp Dermatol2002;27:160–1, doi:10.1046/j.1365-2230.2002.09771.x.
58.
KeohaneSGCorkMJ. Treatment of Grover's disease with calcipotriol (Dovonex). Br J Dermatol1995;132:832–3, doi:10. 1111/j.1365-2133.1995.tb00740.x.
59.
MiljkovicJMarkoPB. Grover's disease: successful treatment with acitretin and calcipotriol. Wien Klin Wochenschr2004;116Suppl 2:81–3.
60.
MotaAVCorreiaTMLopesJMGuimaraesJM. Successful treatment of Grover's disease with calcipotriol. Eur J Dermatol1998;8:33–5.
61.
SimonartT. Topical calcipotriol in the treatment of Darier's disease. Eur J Dermatol1996;6:36–8.
62.
KragballeKSteijlenPMIbsenHH. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization: results of a randomized, double-blind, vehicle-controlled, right/left comparative studyArch Dermatol1995;131:556–60, doi:10. 1001/archderm.1995.01690170058008.
63.
DelfinoMFabbrociniGSammarcoE. Efficacy of calcipotriol versus lactic acid cream in the treatment of lamellar and X-linked ichthyoses. J Dermatol Treat1994;5:151–2, doi:10.3109/09546639409084559.
64.
LuckerGPHSteijlenPMvan de KerkhofPCM. Effect of topical calcipotriol on congenital ichthyoses. Br J Dermatol1995;132, 487, doi:10.1111/j.1365-2133.1995.tb08695.x.
65.
OkanoM. Assessment of the clinical effect of topical tacalcitol on ichthyoses with retentive hyperkeratosis. Dermatology2001;202: 116–8, doi:10.1159/000051609.
66.
ThacherTDFischerPRPettiforJMDarmstadtGL. Nutritional rickets in ichthyosis and response to calcipotriene. Pediatrics2004;114:e119–23, doi:10.1542/peds.114.1.e119.
67.
BogenriederTLandthalerMStolzW. Bullous congenital ichthyosiform erythroderma: safe and effective topical treatment with calcipotriol ointment in a child. Acta Derm Venereol2003; 83:52–4, doi:10.1080/00015550310002738.
68.
UmekojiAFukaiKIshiiM. A case of mosaic-type bullous congenital ichthyosiform erythroderma successfully treated with topical maxacalcitol, a vitamin D3 analogue. Clin Exp Dermatol2008;33:501–2, doi:10.1111/j.1365-2230.2008.02761.x.
69.
GodicADragosV. Successful treatment of Netherton's syndrome with topical calcipotriol. Eur J Dermatol2004;14:115–7.
70.
Fernandez-VozmedianoJMArmario-HitaJCGonzalez-CabrerizoA. Sjogren-Larsson syndrome: treatment with topical calcipotriol. Pediatr Dermatol2003;20:179–80, doi:10.1046/j.1525-1470.2003.20221_1.x.
71.
LuckerGPvan de KerkhofPCCruysbergJR. Topical treatment of Sjogren-Larsson syndrome with calcipotriol. Dermatology1995;190:292–4, doi:10.1159/000246719.
72.
MizunoYSugaYHasegawaT. A case of peeling skin syndrome successfully treated with topical calcipotriol. J Dermatol2006;33:430–2, doi:10.1111/j.1346-8138.2006.00102.x.
73.
BilginIBozdagKEUysalSErmeteM. Progressive symmetrical erythrokeratoderma - response to topical calcipotriol. J Dermatol Case Rep2011;5:50–2, doi:10.3315/jdcr.2011.1075.
74.
WatMYMYeungKHYauKC. Progressive symmetric erythrokeratoderma presenting as hyperkeratotic plaques in a young girl. Hong Kong J Dermatol Venereol2010;18:29–32.
75.
HorikoshiMKurodaKTajimaS. Punctate palmoplantar keratoderma with pigmentary lesions on the dorsa of feet and ankles: successful treatment with a combination of low-dose oral etretinate and topical calcipotriol. J Dermatol2004;31:469–72.
76.
LuckerGPvan de KerkhofPCSteijlenPM. Topical calcipotriol in the treatment of epidermolytic palmoplantar keratoderma of Vorner. Br J Dermatol1994;130:543–5, doi:10.1111/j.1365-2133. 1994.tb03399.x.
77.
YukawaMSatohTHiguchiTYokozekiH. Spiny keratoderma of the palms successfully treated with topical tacalcitol. Acta Derm Venereol2007;87:172–4, doi:10.2340/00015555-0222.
78.
GrossbergEBScherschunLFivensonDP. Ulcerating plantar keratoderma in association with systemic lupus erythematosus. Lupus2001;10:650–2, doi:10.1191/096120301682430258.
79.
AbeMYokoyamaYIshikawaO. Successful treatment of disseminated superficial actinic porokeratosis with tacalcitol lotion. J Dermatol2010;37:913–5, doi:10.1111/j.1346-8138.2010. 00902.x.
80.
BakardzhievIKavaklievaSPehlivanovG. Successful treatment of disseminated superficial actinic porokeratosis with calcipotriol. Int J Dermatol2012;51:1139–42, doi:10.1111/j.1365-4632.2010. 04704.x.
81.
BohmMLugerTABonsmannG. Disseminated superficial actinic porokeratosis: treatment with topical tacalcitol. J Am Acad Dermatol1999;40:479–80, doi:10.1016/S0190-9622(99)70502-5.
NiimiYKawanaS. Type 2 segmental manifestation of disseminated superficial actinic porokeratosis in a 7-year-old girl. Eur J Dermatol2009;19:25–8.
84.
NoborioRMoritaA. Split-face trial of CO(2) laser-induced ring abrasion and high-dose tacalcitol in the treatment of disseminated superficial actinic porokeratosis. J Dermatol2012;39:879–80, doi:10.1111/j.1346-8138.2011.01461.x.
85.
BasakPYBaysalVOzcanliC. Confluent and reticulated papillomatosis: failure of response to calcipotriol and coincidental association with vascular mottling. J Eur Acad Dermatol Venereol2001;15:591–2, doi:10.1046/j.1468-3083.2001.00359.x.
86.
BayramgürlerDApaydinRBilenNMuezzinogluB. Confluent and reticulate papillomatosis: response to topical calcipotriol. J Dermatol Treat2000;11:109–11, doi:10.1080/09546630050517513.
87.
CarrozzoAMGattiSFerrantiG. Calcipotriol treatment of confluent and reticulated papillomatosis (Gougerot-Carteaud syndrome). J Eur Acad Dermatol Venereol2000;14:131–3, doi:10.1046/j.1468-3083.2000.00032.x.
88.
GinarteMFabeiroJMToribioJ. Confluent and reticulated papillomatosis (Gougerot-Carteaud) successfully treated with tacalcitol. J Dermatol Treat2002;13:27–30, doi:10.1080/0954663 0252775216.
89.
GulecATSeckinD. Confluent and reticulated papillomatosis: treatment with topical calcipotriol. Br J Dermatol1999;141:1150–1, doi:10.1046/j.1365-2133.1999.03234.x.
90.
KurkcuogluNCelebiCR. Confluent and reticulated papillomatosis: response to topical calcipotriol. Dermatology1995;191:341–2, doi:10.1159/000246593.
91.
BohmMLugerTAMetzeD. Treatment of mixed-type acanthosis nigricans with topical calcipotriol. Br J Dermatol1998;139:932–4, doi:10.1046/j.1365-2133.1998.02538.x.
92.
Hermanns-LeTHermannsJFPierardGE. Juvenile acanthosis nigricans and insulin resistance. Pediatr Dermatol2002;19:12–4, doi:10.1046/j.1525-1470.2002.00013.x.
93.
GregoriouSAnyfandakisVKontoleonP. Acanthosis nigricans associated with primary hypogonadism: successful treatment with topical calcipotriol. J Dermatol Treat2008;19: 373–5, doi:10.1080/09546630802050506.
94.
BayramgürlerDBilenNApaydinRErcinC. Nevoid hyperkeratosis of the nipple and areola: treatment of two patients with topical calcipotriol. J Am Acad Dermatol2002;46:131–3, doi:10.1067/mjd.2002.117848.
95.
Kartal DurmazlarSPEskiogluFBodurZ. Hyperkeratosis of the nipple and areola: 2 years of remission with low-dose acitretin and topical calcipotriol therapy. J Dermatol Treat2008;19:337–40, doi:10.1080/09546630802051645.
96.
LeeHWChangSELeeMW. Hyperkeratosis of the nipple associated with acanthosis nigricans: treatment with topical calcipotriol. J Am Acad Dermatol2005;52(3 Pt 1):529–30.
97.
BerkDRBoerABauschardFD. Circumscribed acral hypokeratosis. J Am Acad Dermatol2007;57:292–6, doi:10.1016/j.jaad.2007.02.022.
98.
UrbinaFMisadCGonzalezS. Circumscribed palmar hypokeratosis: clinical evolution and ultrastructural study after prolonged treatment with topical calcipotriol. J Eur Acad Dermatol Venereol2005;19:491–4, doi:10.1111/j.1468-3083.2005.01197.x.
99.
KimSHKangJHSeoJK. Successful treatment of lichen spinulosus with topical tacalcitol cream. Pediatr Dermatol2010; 27:546–7, doi:10.1111/j.1525-1470.2010.01275.x.
100.
KimWJSongMKoHC. Topical tacalcitol ointment can be a good therapeutic choice in erythromelanosis follicularis faciei et colli. J Am Acad Dermatol2012;67:320–1, doi:10.1016/j.jaad. 2012.03.008.
101.
SadahiraCYonedaKMoriueT. Successful treatment of keratosis follicularis squamosa with topical tacalcitol. Br J Dermatol2006;154:1010–2, doi:10.1111/j.1365-2133.2006.07208.x.
102.
SmitJVCoxSBlokxWAM. Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol2002;147:816–8, doi:10.1046/j.1365-2133.2002.49297.x.
103.
SeckinDCermanAAYildizAErgunT. Can topical calcipotriol be a treatment alternative in actinic keratoses? A preliminary report. J Drugs Dermatol2009;8:451–4.
104.
HerronMDBowenARKruegerGG. Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod. Int J Dermatol2004;43:300–2, doi:10.1111/j.1365-4632.2004.02282.x.
105.
MitsuhashiYKawaguchiMHozumiYKondoS. Topical vitamin D3 is effective in treating senile warts possibly by inducing apoptosis. J Dermatol2005;32:420–3.
106.
GattiSCarrozzoAMOrlandiANiniG. Treatment of inflammatory linear verrucous epidermal naevus with calcipotriol. Br J Dermatol1995;132:837–9, doi:10.1111/j.1365-2133.1995.tb00744.x.
107.
MicaliGNascaMRMusumeciML. Effect of topical calcipotriol on inflammatory linear verrucous epidermal nevus. Pediatr Dermatol1995;12:386–7, doi:10.1111/j.1525-1470.1995.tb00208.x.
108.
MitsuhashiYKatagariYKondoS. Treatment of inflammatory linear verrucous epidermal naevus with topical vitamin D3. Br J Dermatol1997;136:134–5, doi:10.1111/j.1365-2133.1997.tb08766.x.
109.
ZvulunovAGrunwaldMHHalvyS. Topical calcipotriol for treatment of inflammatory linear verrucous epidermal nevus. Arch Dermatol1997;133:567–8, doi:10.1001/archderm.1997.0389 0410017001.
110.
LeeIWAhnSKChoiEH. Inflammatory linear verrucous epidermal naevus arising on a burn scar. Acta Derm Venereol1999;79:164–5, doi:10.1080/000155599750011462.
111.
GargTKhaitanBKSoodA. Limited role of calcipotriol in inflammatory linear verrucous epidermal naevus. Indian J Dermatol Venereol Leprol2001;67:48–9.
112.
BohmMLugerTATraupeH. Successful treatment of inflammatory linear verrucous epidermal naevus with topical natural vitamin D3 (calcitriol). Br J Dermatol2003;148:824–5, doi:10.1046/j.1365-2133.2003.05194.x.
113.
KarashimaTHashikawaKOnoF. Successful treatment of Bowen's disease with topical maxacalcitol. Acta Derm Venereol2012;92:660–1, doi:10.2340/00015555-1294.
114.
KohMJAChongWS. Systematized epidermal nevus with epidermolytic hyperkeratosis treated with combined calcipotriol/betamethasone dipropionate cream. Australas J Dermatol2012; 53, 41, doi:10.1111/j.1440-0960.2011.00791.x.
115.
DelidukaSBKwongPC. Treatment of nevus comedonicus with topical tazarotene and calcipotriene. J Drugs Dermatol2004;3: 674–6.
TerakiYSatoYIzakiS. Successful treatment of stucco keratosis with maxacalcitol. Br J Dermatol2006;155:1085–6, doi:10.1111/j.1365-2133.2006.07488.x.
118.
ErkekEKurtipekGSDumanD. Eruptive vellus hair cysts: report of a pediatric case with partial response to calcipotriene therapy. Cutis2009;84:295–8.
119.
O'BrienMERTalbotDMacLennanKSmithIE. Inefficacy of calcipotriol in skin metastases from breast cancer. Lancet1993; 342, 994, doi:10.1016/0140-6736(93)92042-R.
120.
BowerMColstonKWSteinRC. Topical calcipotriol treatment in advanced breast cancer [published erratum appears in Lancet 1991;337:1618]. Lancet1991;337:701–2, doi:10.1016/0140-6736(91)90280-3.
121.
StollFAkladiosCYMathelinC. [Vitamin D and breast cancer: is there a link?]Gynecol Obstet Fertil2013;41:242–50, doi:10.1016/j.gyobfe.2013.02.002.
122.
SwamiSKrishnanAVPengL. Transrepression of the estrogen receptor promoter by calcitriol in human breast cancer cells via two negative vitamin D response elements. Endocr Relat Cancer2013 Jun 6. [Epub ahead of print]
123.
Ascari-RaccagniADondasADubiniA. Biopsy proven morphea treated with tacalcitol ointment: case report. Acta Dermatovenerol Croat2010;18:248–51.
124.
CunninghamBBLandellsIDRLangmanC. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol1998;39:211–5, doi:10.1016/S0190-9622(98)70077-5.
125.
DytocMTKossintsevaITingPT. First case series on the use of calcipotriol-betamethasone dipropionate for morphoea. Br J Dermatol2007;157:615–8, doi:10.1111/j.1365-2133.2007.07971.x.
126.
KreuterAGambichlerTAvermaeteA. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol2001; 18:241–5, doi:10.1046/j.1525-1470.2001.018003241.x.
127.
PayapvipapongKAunhachokeK. Generalized morphea: a case report. J Med Assoc Thai2010;93Suppl 6:S215–7.
128.
SantosGSousaLJoaoAPaiva LopesMJ. Linear morphea - a case treated with calcipotriol and betamethasone dipropionate. Eur J Pediatr Dermatol2012;22:284.
129.
TayYK. Topical calcipotriol ointment in the treatment of morphea. J Dermatol Treat2003;14:219–21, doi:10.1080/09546 630310015449.
130.
GambichlerTKreuterARotterdamS. Linear scleroderma ‘en coup de sabre’ treated with topical calcipotriol and cream psoralen plus ultraviolet A. J Eur Acad Dermatol Venereol2003; 17:601–2, doi:10.1046/j.1468-3083.2003.00626.x.
131.
ZwischenbergerBAJacobeHT. A systematic review of morphea treatments and therapeutic algorithm. J Am Acad Dermatol2011; 65:925–41, doi:10.1016/j.jaad.2010.09.006.
GuptaSSaraswatAKumarB. Treatment of genital lichen sclerosus with topical calcipotriol. Int J STD AIDS2005;16:772–4, doi:10.1258/095646205774763234.
134.
KreuterAGambichlerTSauermannK. Extragenital lichen sclerosus successfully treated with topical calcipotriol: evaluation by in vivo confocal laser scanning microscopy. Br J Dermatol2002;146:332–3, doi:10.1046/j.1365-2133.2002.4653_3.x.
135.
LazaridouEGiannopoulouCApallaZ. Parry-Romberg syndrome. J Dermatol Case Rep2010;4:30–2, doi:10.3315/jdcr. 2010.1049.
136.
BayramgürlerDApaydinRBilenN. Limited benefit of topical calcipotriol in lichen planus treatment: a preliminary study. J Dermatol Treat2002;13:129–32, doi:10.1080/09546 630260199497.
137.
BoulocARevuzJBagotM. KH 1060 for the treatment of lichen planus: a multicenter, randomized, double-blind, vehicle-controlled study. Arch Dermatol2000;136, 1272, doi:10.1001/archderm.136.10.1272.
138.
ThengCTTanSHGohCL. A randomized controlled trial to compare calcipotriol with betamethasone valerate for the treatment of cutaneous lichen planus. J Dermatol Treat2004;15: 141–5, doi:10.1080/09546630410031891.
139.
GladeCPvan Der VleutenCJvan ErpPE. The epidermis of chronic idiopathic lichen planus during topical treatment with the vitamin D3 analogue KH 1060. Clin Exp Dermatol1998;23:14–8, doi:10.1046/j.1365-2230.1998.00287.x.
140.
Moreno-CruzBTorres-AlvarezBHernandez-BlancoDCastanedo-CazaresJP. Double-blind, placebo-controlled, randomized study comparing 0.0003% calcitriol with 0.1% tacrolimus ointments for the treatment of endemic pityriasis alba. Dermatol Res Pract2012;2012:303275.
WongSSGohCL. Double-blind, right/left comparison of calcipotriol ointment and betamethasone ointment in the treatment of prurigo nodularis. Arch Dermatol2000;136:807–8, doi:10.1001/archderm.136.6.807.
143.
ContrerasMEGottfriedLCBangRHPalmerCH. Axillary intertriginous granular parakeratosis responsive to topical calcipotriene and ammonium lactate. Int J Dermatol2003;42:382–3, doi:10.1046/j.1365-4362.2003.01722.x.
144.
PatelUPatelTSkinnerRBJr. Resolution of granular parakeratosis with topical calcitriol. Arch Dermatol2011;147: 997–8, doi:10.1001/archdermatol.2011.214.
145.
SamraoAReisMNiedtGRudikoffD. Granular parakeratosis: response to calcipotriene and brief review of current therapeutic options. SKINmed2010;8:357–9.
146.
UrbinaFSudyEMisadC. Two episodes of axillary granular parakeratosis triggered by different causes: case report. Acta Dermatovenerol Croat2012;20:105–7.
147.
GrunwaldMHHallel-HalevyDAmichaiB. Keratosis lichenoides chronica: response to topical calcipotriol. J Am Acad Dermatol1997;37(2 Pt 1):263–4, doi:10.1016/S0190-9622(97)80136-3.
AdisenEErdemOCelepciSGurerMA. Easy to diagnose, difficult to treat: keratosis lichenoides chronicaClin Exp Dermatol2010;35:47–50, doi:10.1111/j.1365-2230.2009.03520.x.
150.
DemirciEBoyvatAAricaIE. Keratosis lichenoides chronica: marked response to PUVA in combination with acitretin. Acta Derm Venereol2005;85:552–3.
151.
AvermaeteAKreuterJAStuckerM. Keratosis lichenoides chronica: characteristics and response to acitretin. Br J Dermatol2001;144:422–4, doi:10.1046/j.1365-2133.2001.04044.x.
152.
GhislainPDDe BeirACreusyCModianoP. Keratosis lichenoides chronica: report of a new case, with success of PUVA therapy. Dermatol Online J2001;7(1):4.
153.
TadakiTKatoTTagamiH. Topical active vitamin D3 analogue, 1,24-dihydroxycholecalciferol, an effective new treatment for facial seborrhoeic dermatitis. J Dermatol Treat1996;7:139–41, doi:10.3109/09546639609086874.
154.
KowalzickLSchlehaiderUK. An open pilot study of topical calcipotriol in seborrhoeic eczema. J Dermatol Treat1998;9:49–51, doi:10.3109/09546639809160691.
155.
NakayamaJ. Four cases of sebopsoriasis or seborrheic dermatitis of the face and scalp successfully treated with 1a-24 (R)-dihydroxycholecalciferol (tacalcitol) cream. Eur J Dermatol2000; 10:528–32.
156.
BasakPYErginS. Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp. J Eur Acad Dermatol Venereol2001;15:86–8, doi:10.1046/j.1468-3083.2001.00193-9.x.
157.
Berth-JonesJAdnittPI. Topical calcipotriol is not effective in facial seborrhoeic dermatitis. J Dermatol Treat2001;12, 179, doi:10.1080/09546630152608339.
158.
EgawaK. Topical vitamin D3 derivatives in treating hyperkeratotic palmoplantar eczema: a report of five patients. J Dermatol2005;32:381–6.
159.
JaimovichLMordohASchrohR. Treatment of circumscribed juvenile type of pityriasis rubra pilaris with calcipotriol. J Dermatol Treat1997;8:211–2, doi:10.3109/09546639709160521.
160.
Van de KerkhofPCSteijlenPM. Topical treatment of pityriasis rubra pilaris with calcipotriol. Br J Dermatol1994;130:675–8, doi:10.1111/j.1365-2133.1994.tb13121.x.
KawaguchiMMitsuhashiYKondoS. A case of subcorneal pustular dermatosis treated with tacalcitol (1alpha,24-dihydroxyvitamin D3). J Dermatol2000;27:669–72.
164.
BoffaMJ. Erosive pustular dermatosis of the scalp successfully treated with calcipotriol cream. Br J Dermatol2003;148:593–5, doi:10.1046/j.1365-2133.2003.05209_2.x.
165.
EgawaKOnoT. Topical vitamin D3 derivatives for recalcitrant warts in three immunocompromised patients. Br J Dermatol2004;150:374–6, doi:10.1111/j.1365-2133.2003.05766.x.
166.
LabandeiraJVazquez-BlancoMParedesC. Efficacy of topical calcipotriol in the treatment of a giant viral wart. Pediatr Dermatol2005;22:375–6, doi:10.1111/j.1525-1470.2005.22425.x.
167.
InabaHSuzukiTAdachiATomitaY. Successful treatment of warts with a combination of maxacalcitol ointment and salicylic acid sticking plaster. J Dermatol2006;33:383–5, doi:10.1111/j.1346-8138.2006.00090.x.
168.
ImagawaISuzukiH. Successful treatment of refractory warts with topical vitamin D3 derivative (maxacalcitol, 1alpha, 25-dihydroxy-22-oxacalcitriol) in 17 patients. J Dermatol2007;34: 264–6, doi:10.1111/j.1346-8138.2007.00266.x.
169.
RindTOisoNKawadaA. Successful treatment of anogenital wart with a topical vitamin D3 derivative in an infant. Case Rep Dermatol2010;2:46–9, doi:10.1159/000312986.
170.
MuraoKOshimaMMiyajimaOKuboY. Verrucous skin lesions on the feet in diabetic neuropathy successfully treated with topical maxacalcitol. Eur J Dermatol2012;22:274–5.
171.
HayashiJMatsuiCMitsuishiT. Treatment of localized epidermodysplasia verruciformis with tacalcitol ointment. Int J Dermatol2002;41:817–20, doi:10.1046/j.1365-4362.2002. 01642.x.
172.
Berth-JonesJHutchinsonPE. Alopecia totalis does not respond to the vitamin-D analogue calcipotriol. J Dermatol Treat1991;1: 293–4, doi:10.3109/09546639109086760.
173.
OrecchiaGAlbani RocchettiG. Topical use of calcipotriol does not potentiate squaric acid dibutylester effectiveness in the treatment of alopecia areata. J Dermatol Treat1995;6:21–3, doi:10.3109/09546639509080585.
174.
HidalgoMRinaldiDMedinaG. A phase I trial of topical topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to prevent chemotherapy-induced alopecia. Anticancer Drugs1999;10:393–5, doi:10.1097/00001813-199904000-00007.
175.
BleikerTONicolaouNTraulsenJHutchinsonPE. ‘Atrophic telogen effluvium’ from cytotoxic drugs and a randomized controlled trial to investigate the possible protective effect of pretreatment with a topical vitamin D analogue in humans. Br J Dermatol2005;153:103–12, doi:10.1111/j.1365-2133.2005. 06608.x.
176.
Gruber-WackernagelABambachILegatFJ. Randomized double-blinded placebo-controlled intra-individual trial on topical treatment with a 1,25-dihydroxyvitamin D3 analogue in polymorphic light eruption. Br J Dermatol2011;165:152–63, doi:10.1111/j.1365-2133.2011.10333.x.
177.
ParkJMMunJHJwaSW. Efficacy and safety of calcipotriol/betamethasone dipropionate ointment for the treatment of trachyonychia: an open-label study. J Dermatol2012;39: 48, doi:10.1111/j.1346-8138.2011.01299.x.
178.
KhooBPTayYKGohCL. Calcipotriol ointment vs. betamethasone 17-valerate ointment in the treatment of lichen amyloidosis. Int J Dermatol1999;38:539–41, doi:10.1046/j.1365-4362.1999.00714.x.
179.
van der VeerWMJacobsXEWaardenburgIE. Topical calcipotriol for preventive treatment of hypertrophic scars: a randomized, double-blind, placebo-controlled trial. Arch Dermatol2009;145:1269–75, doi:10.1001/archdermatol.2009.237.
180.
FemianoFGombosFScullyC. Oral leukoplakia: open trial of topical therapy with calcipotriol compared with tretinoin. Int J Oral Maxillofac Surg2001;30:402–6, doi:10.1054/ijom.2001. 0107.
181.
Hernandez RuizEGarciaANavarraEFerrandoJ. Elastosis perforans serpiginosa with an atypical and widespread presentation. Eur J Pediatr Dermatol2012;22:45–6.
182.
GniadeckiR. Calcipotriol for erythema annulare centrifugum. Br J Dermatol2002;146:317–9, doi:10.1046/j.0007-0963.2001.04572.x.
BatallaACarpinteroMLDe la TorreC. Disseminated epidermolytic acanthoma with partial response to calcipotriol ointment. J Dermatol2013;40:144–5, doi:10.1111/1346-8138.12016.
185.
MoriartyBKennedyCBourkeJFFitzgibbonJ. Lupus vulgaris responding to calcipotriol. J Am Acad Dermatol2009;60(3Suppl 1): AB106.
186.
BlahetaHJMetzlerGRassnerGGarbeC. Hyperkeratosis lenticularis perstans (Flegel's disease)—lack of response to treatment with tacalcitol and calcipotriol. Dermatology2001;202:255–8, doi:10.1159/000051648.
187.
KimDHLeeJWKimIS. Successful treatment of alopecia areata with topical calcipotriol. Ann Dermatol2012;24:341–4, doi:10.5021/ad.2012.24.3.341.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
